Get news updates from AACRMeetingNews.org
Subscribe below to get email updates from AACRMeetingNews.org
During a plenary session on Tuesday, April 12, four researchers discussed the latest advances in immuno-oncology, including developments in the understanding of immunotherapy modalities, efficacy, and combination strategies. Carl H. June, MD, FAACR, chaired the session.
The Annual Meeting’s final Clinical Trials Plenary Session featured trials of immunotherapy drug combinations that could benefit patients who don’t respond to single-agent immunotherapy or chemotherapy combinations. Timothy A. Yap, MD, PhD, chaired the session.
Annual Meeting Program Committee Chair Marcia R. Cruz-Correa, MD, PhD, shares a few highlights from Wednesday’s schedule to help plan your day.
Organized by the AACR Chemistry in Cancer Research working group, this year’s three “New Drugs on the Horizon” sessions featured first disclosures of the discovery and structure of 12 novel agents.
“There are some very novel drugs targeting the DNA damage response pathway that are being developed, including some presented for the very first time during this session,” said Julie R. Brahmer, MD, MSc, co-chair of the Annual Meeting Clinical Trials Committee.
National Cancer Institute Principal Deputy Director Douglas R. Lowy, MD, FAACR, visited the AACR Annual Meeting on Monday, April 11. He becomes NCI acting director at the end of April when Norman E. Sharpless, MD, FAACR, steps down as head of the NCI.
Trey Ideker, PhD, led a Monday morning session on interpreting and building trust in artificial intelligence models in cancer research. AI techniques hold promise but still lack interpretability and transferability in translational medicine, he said.